Zurlinden Todd J, Reisfeld Brad
Department of Chemical and Biological Engineering, Colorado State University, 1370 Campus Delivery, Fort Collins, CO, 80523-1370, USA.
School of Biomedical Engineering, Colorado State University, Fort Collins, CO, 80523, USA.
Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):143-153. doi: 10.1007/s13318-016-0329-2.
Acetaminophen (APAP, paracetamol) is currently the principal cause of acute liver failure in both the USA and the UK. However, relatively little is known about the influence of genes and race/ethnicity on the disposition of APAP and the extent to which genetic variation and ethnicity may predispose individuals to a higher risk of APAP-induced hepatotoxicity. The objective of this research was to develop subpopulation-specific physiologically based pharmacokinetic (PBPK) models for two genetically different groups (Western Europeans and East Asians) and then use the models to quantify the difference in absorption, distribution, metabolism, and excretion (ADME) of APAP between these groups.
A comprehensive set of human pharmacokinetic data mined from the literature was divided into two groups based on ethnicity as an indicator of the expected abundance of phenol-metabolizing alleles. Using these datasets and a Bayesian hierarchical framework, subpopulation-specific physiologically based pharmacokinetic models for APAP were developed and tested for the two groups.
Model simulations were in good agreement with experimental data for both time-dependent parent and metabolite concentrations and summary pharmacokinetic parameters. In addition, simulations were conducted to characterize the difference between ADME in these groups with regard to urinary excretion and APAP area under the curve (AUC) in the liver. Although not dramatic at therapeutic dosing levels, these results demonstrated the divergence in the liver-specific APAP concentrations and AUC between the two groups and suggested that differences in glucuronidation capacity may play a role in this disparity.
Overall, the models developed in this study, and others created using this type of hierarchical methodology, are expected to be useful in quantifying ADME in a subpopulation-specific manner and reducing prediction uncertainty compared to that from generalized PBPK modeling approaches.
对乙酰氨基酚(APAP,扑热息痛)目前是美国和英国急性肝衰竭的主要病因。然而,关于基因和种族对APAP处置的影响以及基因变异和种族在多大程度上可能使个体易患APAP诱导的肝毒性的风险增加,人们了解得相对较少。本研究的目的是为两个基因不同的群体(西欧人和东亚人)建立亚群特异性的基于生理的药代动力学(PBPK)模型,然后使用这些模型量化这两个群体之间APAP在吸收、分布、代谢和排泄(ADME)方面的差异。
从文献中挖掘的一组全面的人体药代动力学数据,根据种族作为酚代谢等位基因预期丰度的指标分为两组。利用这些数据集和贝叶斯分层框架,为这两个群体开发并测试了APAP的亚群特异性基于生理的药代动力学模型。
模型模拟结果与实验数据在随时间变化的母体和代谢物浓度以及汇总药代动力学参数方面均吻合良好。此外,还进行了模拟以表征这些群体在尿排泄和肝脏中APAP曲线下面积(AUC)方面ADME的差异。尽管在治疗剂量水平上差异不显著,但这些结果表明两组之间肝脏特异性APAP浓度和AUC存在差异,并表明葡萄糖醛酸化能力的差异可能在这种差异中起作用。
总体而言,本研究中开发的模型以及使用这种分层方法创建的其他模型,预计将有助于以亚群特异性方式量化ADME,并与广义PBPK建模方法相比降低预测不确定性。